Medicine & Life Sciences
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
100%
Imatinib Mesylate
80%
Acute Myeloid Leukemia
66%
Leukemia, Myeloid, Chronic Phase
52%
Protein-Tyrosine Kinases
47%
Cytogenetics
31%
Philadelphia Chromosome
30%
Dasatinib
28%
Cytarabine
26%
Survival
25%
Myelodysplastic Syndromes
25%
Leukemia
24%
Precursor Cell Lymphoblastic Leukemia-Lymphoma
24%
Therapeutics
23%
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide
23%
Primary Myelofibrosis
16%
Mutation
16%
bosutinib
15%
Blast Crisis
12%
Drug Therapy
11%
ponatinib
11%
Phosphotransferases
10%
Idarubicin
9%
Decitabine
9%
GATA2 Deficiency
9%
Safety
9%
fludarabine
8%
Homoharringtonine
8%
Neoplasms
8%
Allogeneic Cells
8%
Bone Marrow
8%
Hematologic Neoplasms
8%
Stem Cell Transplantation
7%
Cyclophosphamide
7%
Progression-Free Survival
7%
Gemtuzumab
7%
Recurrence
7%
Chromosome Aberrations
7%
B-Cell Chronic Lymphocytic Leukemia
7%
Acute Promyelocytic Leukemia
6%
Azacitidine
6%
1-(2-(1H-benzo(d)imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea
6%
Leukemia, Myelomonocytic, Chronic
6%
Vincristine
6%
Clofarabine
6%
asciminib
6%
Polycythemia Vera
5%
Clinical Trials
5%
Survival Rate
5%
Interferons
5%